Marc A. Pfeffer
YOU?
Author Swipe
View article: #1394 Endothelin-1 and cardio-kidney events among patients with CKD, diabetes, and anemia
#1394 Endothelin-1 and cardio-kidney events among patients with CKD, diabetes, and anemia Open
Background and Aims Endothelin-1 (ET-1) is a potent vasoconstrictor and is implicated in the pathogenesis of proteinuria and progressive chronic kidney disease (CKD). With the development of ET-1 receptor antagonists, there is interest in …
View article: Multiparametric Assessment of Right Ventricular Dysfunction in Heart Failure: An Analysis From PARAGON‐HF
Multiparametric Assessment of Right Ventricular Dysfunction in Heart Failure: An Analysis From PARAGON‐HF Open
Background This study aims to characterize right ventricular dysfunction (RVD) in heart failure (HF) with preserved ejection fraction and understand the cumulative prognostic value of abnormal RV echocardiographic parameters in HF with pre…
View article: Systolic Blood Pressure and Pulse Pressure in Heart Failure
Systolic Blood Pressure and Pulse Pressure in Heart Failure Open
View article: Visit‐to‐visit changes in heart rate in heart failure: A pooled participant‐level analysis of the <scp>PARADIGM</scp>‐<scp>HF</scp> and <scp>PARAGON</scp>‐<scp>HF</scp> trials
Visit‐to‐visit changes in heart rate in heart failure: A pooled participant‐level analysis of the <span>PARADIGM</span>‐<span>HF</span> and <span>PARAGON</span>‐<span>HF</span> trials Open
Aims Resting heart rate (HR) is a strong risk marker in patients with heart failure (HF), but the clinical implications of visit‐to‐visit changes in HR (ΔHR) are less well established. We aimed to explore the association between ΔHR and su…
View article: Therapeutic Effects of Heart Failure Medical Therapies on Standardized Kidney Outcomes: Comprehensive Individual Participant–Level Analysis of 6 Randomized Clinical Trials
Therapeutic Effects of Heart Failure Medical Therapies on Standardized Kidney Outcomes: Comprehensive Individual Participant–Level Analysis of 6 Randomized Clinical Trials Open
BACKGROUND: Kidney outcomes have been variably defined using nonstandardized composite end points in key heart failure trials, thus introducing complexity in their interpretation and cross-trial comparability. We examined the effects of st…
View article: Natriuretic Peptides, Kidney Function, and Clinical Outcomes in Heart Failure With Preserved Ejection Fraction
Natriuretic Peptides, Kidney Function, and Clinical Outcomes in Heart Failure With Preserved Ejection Fraction Open
The same NT-proBNP concentration predicts a substantially higher absolute risk of adverse outcomes for people with heart failure and reduced kidney function, compared with those with preserved kidney function. These data call into question…
View article: Rates of Sudden Death After Myocardial Infarction—Insights From the VALIANT and PARADISE-MI Trials
Rates of Sudden Death After Myocardial Infarction—Insights From the VALIANT and PARADISE-MI Trials Open
Importance Sudden death is a leading cause of death after acute myocardial infarction (AMI). The Prospective ARNi vs ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After MI (PARADISE-MI) and Valsartan in Acut…
View article: Incidence of clinical outcomes in heart failure patients with and without advanced chronic kidney disease
Incidence of clinical outcomes in heart failure patients with and without advanced chronic kidney disease Open
Aims Chronic kidney disease (CKD) is a well‐established risk factor for heart failure (HF); however, patients with an estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m 2 have been systematically excluded from clinical trials. …
View article: Aptamer Proteomics for Biomarker Discovery in Heart Failure With Preserved Ejection Fraction: The PARAGON‐HF Proteomic Substudy
Aptamer Proteomics for Biomarker Discovery in Heart Failure With Preserved Ejection Fraction: The PARAGON‐HF Proteomic Substudy Open
Background Prognostic markers and biological pathways linked to detrimental clinical outcomes in heart failure with preserved ejection fraction (HFpEF) remain incompletely defined. Methods and Results We measured serum levels of 4123 uniqu…
View article: Safety and Tolerability of Angiotensin Receptor-Neprilysin Inhibitor Initiation in High-Risk Acute Myocardial Infarction Relative to Care Setting: A Subgroup Analysis of the PARADISE-MI Trial
Safety and Tolerability of Angiotensin Receptor-Neprilysin Inhibitor Initiation in High-Risk Acute Myocardial Infarction Relative to Care Setting: A Subgroup Analysis of the PARADISE-MI Trial Open
View article: Revisiting Race and the Benefit of RAS Blockade in Heart Failure
Revisiting Race and the Benefit of RAS Blockade in Heart Failure Open
Importance Concerns have arisen that renin-angiotensin system (RAS) blockers are less effective in Black patients than non-Black patients with heart failure and reduced ejection fraction (HFrEF). Objective To determine whether the effects …
View article: Cardiovascular-Kidney-Metabolic Overlap in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Cardiovascular-Kidney-Metabolic Overlap in Heart Failure With Mildly Reduced or Preserved Ejection Fraction Open
View article: Angiotensin Receptor-Neprilysin Inhibition in Patients With STEMI vs NSTEMI
Angiotensin Receptor-Neprilysin Inhibition in Patients With STEMI vs NSTEMI Open
View article: High-sensitivity C-reactive protein in heart failure with preserved ejection fraction: Findings from TOPCAT
High-sensitivity C-reactive protein in heart failure with preserved ejection fraction: Findings from TOPCAT Open
View article: Pulmonary Congestion and Left Ventricular Dysfunction After Myocardial Infarction: Insights From the PARADISE-MI Trial
Pulmonary Congestion and Left Ventricular Dysfunction After Myocardial Infarction: Insights From the PARADISE-MI Trial Open
View article: New Clinical Challenges for Health Providers in the Prescription of Statins in the Elderly
New Clinical Challenges for Health Providers in the Prescription of Statins in the Elderly Open
View article: Sacubitril/valsartan compared to ramipril in high‐risk post‐myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: Insight from the <scp>PARADISE MI</scp> trial
Sacubitril/valsartan compared to ramipril in high‐risk post‐myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: Insight from the <span>PARADISE MI</span> trial Open
Aim It is unknown whether safety and clinical endpoints by use of sacubitril/valsartan (an angiotensin receptor–neprilysin inhibitor [ARNI]) are affected by mineralocorticoid receptor antagonists (MRA) in high‐risk myocardial infarction (M…
View article: Echocardiographic characterization of patients with supranormal ejection fraction: pooled core laboratory analysis of the TOPCAT and PARAGON-HF trials
Echocardiographic characterization of patients with supranormal ejection fraction: pooled core laboratory analysis of the TOPCAT and PARAGON-HF trials Open
Background Patients with heart failure and supranormal ejection fraction (HFsnEF) may be phenotypically distinct from those with normal or below normal left ventricular ejection fraction (LVEF), and may demonstrate different prognostic tra…
View article: Heart failure with preserved ejection fraction, red cell distribution width, and sacubitril/valsartan
Heart failure with preserved ejection fraction, red cell distribution width, and sacubitril/valsartan Open
Aims Red cell distribution width (RDW) is a strong prognostic marker in patients with heart failure (HF) and reduced ejection fraction and other conditions. However, very little is known about its prognostic significance in HF with preserv…
View article: Health and Economic Evaluation of Sacubitril-Valsartan for Heart Failure Management
Health and Economic Evaluation of Sacubitril-Valsartan for Heart Failure Management Open
Importance The US Food and Drug Administration expanded labeling of sacubitril-valsartan from the treatment of patients with chronic heart failure (HF) with reduced ejection fraction (EF) to all patients with HF, noting the greatest benefi…
View article: Issue Information
Issue Information Open
Despite warnings, co-medication with proton pump inhibitors and dasatinib is common in chronic myeloid leukemia
View article: Sex Differences in Clinical Characteristics and Outcomes After Myocardial Infarction With Low Ejection Fraction: Insights From PARADISE‐MI
Sex Differences in Clinical Characteristics and Outcomes After Myocardial Infarction With Low Ejection Fraction: Insights From PARADISE‐MI Open
Background Studies demonstrated sex differences in outcomes following acute myocardial infarction, with women more likely to develop heart failure (HF). Sacubitril/valsartan has been shown to reduce cardiovascular death and HF hospitalizat…
View article: Declining risk of heart failure hospitalization following first acute myocardial infarction in Scotland between 1991–2016
Declining risk of heart failure hospitalization following first acute myocardial infarction in Scotland between 1991–2016 Open
Aim Mortality from acute myocardial infarction (AMI) has declined, increasing the pool of survivors at risk of later development of heart failure (HF). However, coronary reperfusion limits infarct size and secondary prevention therapies ha…
View article: Clinical Characteristics and Outcomes in Patients With Heart Failure: Are There Thresholds and Inflection Points in Left Ventricular Ejection Fraction and Thresholds Justifying a Clinical Classification?
Clinical Characteristics and Outcomes in Patients With Heart Failure: Are There Thresholds and Inflection Points in Left Ventricular Ejection Fraction and Thresholds Justifying a Clinical Classification? Open
BACKGROUND: Recent guidelines proposed a classification for heart failure (HF) on the basis of left ventricular ejection fraction (LVEF), although it remains unclear whether the divisions chosen were biologically rational. Using patients s…
View article: Stroke in patients with heart failure and reduced or preserved ejection fraction
Stroke in patients with heart failure and reduced or preserved ejection fraction Open
Aims Stroke is an important problem in patients with heart failure (HF), but the intersection between the two conditions is poorly studied across the range of ejection fraction. The prevalence of history of stroke and related outcomes were…
View article: Predicting Stroke in Heart Failure and Preserved Ejection Fraction Without Atrial Fibrillation
Predicting Stroke in Heart Failure and Preserved Ejection Fraction Without Atrial Fibrillation Open
BACKGROUND: The rate of stroke in patients with heart failure (HF) and preserved ejection fraction but without atrial fibrillation (AF), is uncertain as is whether it is possible to reliably predict the risk of stroke in these patients. ME…
View article: Right Ventricular Function and Pulmonary Coupling in Patients With Heart Failure and Preserved Ejection Fraction
Right Ventricular Function and Pulmonary Coupling in Patients With Heart Failure and Preserved Ejection Fraction Open
View article: Rapid, accurate publication and dissemination of clinical trial results: benefits and challenges
Rapid, accurate publication and dissemination of clinical trial results: benefits and challenges Open
Large-scale clinical trials are essential in cardiology and require rapid, accurate publication, and dissemination. Whereas conference presentations, press releases, and social media disseminate information quickly and often receive consid…
View article: Prognostic Importance of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) Following High-Risk Myocardial Infarction in the PARADISE-MI Trial
Prognostic Importance of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) Following High-Risk Myocardial Infarction in the PARADISE-MI Trial Open
Background: NT-proBNP (N-terminal pro-B-type natriuretic peptide) is a potent predictor of death and heart failure (HF) across multiple populations. We evaluated the prognostic importance of NT-proBNP in patients with acute myocardial infa…
View article: Geographic differences in patients with acute myocardial infarction in the <scp>PARADISE‐MI</scp> trial
Geographic differences in patients with acute myocardial infarction in the <span>PARADISE‐MI</span> trial Open
Aim The globalization of clinical trials has highlighted geographic differences in patient characteristics, treatments, and outcomes. We examined these differences in PARADISE‐MI. Methods and results Overall, 23.0% were randomized in Easte…